Loading viewer...
earnings
Format: PDF earnings
Natera reported strong 2021 results with 1.57M tests processed and $625.5M revenue (+60% YoY), alongside landmark clinical achievements including the CIRCULATE-Japan study validating Signatera MRD for colorectal cancer and publication of the SMART 22q11.2 deletion trial. The company guided 2022 revenue of $770-790M, reflecting continued momentum in its non-invasive prenatal testing and oncology diagnostics businesses.
earnings
21 Pages
earnings
7 Pages
Alma Media
Maruti Suzuki Q2 FY24 H1 FY24 Financial Results 2023
earningsearnings
18 Pages
Maruti Suzuki India Limited